Targeting metabolism in aggressive childhood blood cancers
Prof Jonathan Bond and Dr Marie-Claire Fitzgerald aim to find a treatment that can exploit a key weakness of acute myeloid leukaemia.
Investigating the role of SET in childhood acute myeloid leukaemia to develop new treatments
Dr Maria Teresa Esposito hopes to learn more about a gene called SET in leukaemia and will test the best medicines to fight it.
Finding the most beneficial dose of fludarabine to optimise CAR-T therapy
Dr Shelby Barnett and Dr Geoff Shenton will monitor crucial drug levels in patients' blood in order to improve CAR T therapy protocols.
Fighting circular DNA to prevent relapse in acute lymphoblastic leukaemia
Looking at whether medicines that prevent circular DNA replication can help prevent relapse.
Why do some leukaemia patients have long-term problems with learning and memory
Finding a way to identify patients at risk of brain related side effects from leukaemia treatment, and gathering data to inform future treatment options.
Designing a safer way to find and fight acute myeloid leukaemia cells in children
Investigating a protein found on leukaemia stem cells, the cells which cause relapse, and whether it could be a good drug target.
Studying the origins of childhood acute myeloid leukaemia to identify targets for kinder and more effective treatments
Learning more about leukaemia cells in order to design targeted treatments that can increase survivorship and quality of life.
Developing ways to identify chemotherapy resistant B-cell acute lymphoblastic leukaemia cells
Developing a test that can measure the amount of chemotherapy-resistant leukaemia cells in patient's blood samples. This would provide the foundations for future research.
Could a medicine called ONC-201 help treat children with T-cell acute lymphoblastic leukaemia?
Looking at whether a pre-existing drug could be an effective and safe treatment due to its ability to target cancer cells directly.